jRCT2031230429进行中（未招募）不适用
ONO-7475-04:A Phase1 study to examine tolerability and safety of ONO-7475 in combination with ONO-4538 and gemcitabine plus nab-paclitaxel (GnP), the standard of care, and safety of ONO-7475 in combination with GnP in patients with metastatic pancreatic cancer as first-line treatment
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 87
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Open(masking Not Used)
入排标准
- 年龄范围
- 18age old over 至 No limit（—）
- 性别
- All
入选标准
- •1.Patient with metastatic pancreatic cancer
- •2.Patients have an ECOG performance status of 0 to 1
- •3.Patients with a life expectancy of at least 6 months
排除标准
- •1.Patients are unable to swallow oral medications
- •2.Patients with severe complication
结局指标
主要结局
-
Safety and tolerability
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Study of ONO-7475 in Combination With Osimertinib in EGFR Gene Mutation-positive Non-small Cell Lung CancerStage IIIB Non-small Cell Lung CancerStage IIIC Non-Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non-Small Cell Lung CancerEGFR Mutation-Related TumorsNCT06525246Ono Pharmaceutical Co. Ltd78
进行中（未招募）
1 期
A PhaseⅠStudy of ONO-7475 in Combination With ONO-4538 and Gemcitabine Plus Nab-paclitaxel (GnP), the Standard of Care, and ONO-7475 in Combination With GnP in Patients With Pancreatic CancerMetastatic Pancreatic CancerNCT06532331Ono Pharmaceutical Co. Ltd87
已完成
2 期
Study of ONO-8577 in Patients With Overactive BladderOveractive BladderNCT03106623Ono Pharmaceutical Co. Ltd207
未知
1 期
ONO-6950 Phase 1 StudyAsthmaJPRN-jRCT2080221601ONO PHARMACEUTICAL CO.,LTD.52
进行中（未招募）
1 期
ONO-7475-03 : ONO-7475 Phase 1 StudyEGFR mutated, stage IIIB/IIIC/IV or recurrent, NSCLC, which is unsuitable for radical irradiationJPRN-jRCT2051210045Osawa Masahiro75